<DOC>
	<DOCNO>NCT01084330</DOCNO>
	<brief_summary>A clinical trial determine effectiveness safety AUY922 compare drug know effective gastric cancer second line therapy patient fail one line chemotherapy .</brief_summary>
	<brief_title>Phase II Trial AUY922 vs. Comparators Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Radiologically confirm advanced gastric cancer One previous line chemotherapy Progressive disease One measurable lesion Blood test within protocol range ( WHO ) Performance Status â‰¤ 1 Able sign inform consent No symptomatic brain metastases No coumarin type anticoagulants No liver kidney disease No impaired heart function No pregnant lactate woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>metastatic gastric cancer</keyword>
	<keyword>advanced gastric cancer</keyword>
</DOC>